NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
MWN-AI** Summary
NervGen Pharma Corp. (NASDAQ: NGEN), a clinical-stage biopharmaceutical company focused on developing innovative neuroreparative therapeutics for spinal cord injury (SCI) and other neurological conditions, recently announced its participation in two significant investor events. On April 15, 2026, Adam Rogers, MD, President and CEO, and the executive leadership will engage in a fireside chat as part of the H.C. Wainwright "HCW@Home" series, running from 1:00 to 2:00 PM ET. Following that, NervGen will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 22, from 11:00 to 11:30 AM ET.
NervGen's lead therapeutic candidate, NVG-291, represents a groundbreaking approach to treating SCI and improving the quality of life for individuals suffering from chronic tetraplegia. NVG-291, a subcutaneously administered peptide, targets the inhibitory CSPG-PTP pathway and has achieved notable recognition, including Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency.
The Company aims to transform neurological treatment paradigms focusing on unmet medical needs through its lead and next-generation candidate, NVG-300. This participation at major conferences underscores NervGen's commitment to advancing its innovative therapies and engaging with investors. A live webcast of both events will be available on the NervGen website, providing further opportunities for interested stakeholders to learn about the Company's advancements.
For more information on NervGen and its pipeline, visit www.nervgen.com. However, investors should exercise caution regarding forward-looking statements highlighted in the release, as outcomes depend on various factors including clinical trial results and regulatory approvals.
MWN-AI** Analysis
NervGen Pharma Corp. (NASDAQ: NGEN) is positioned at the forefront of neuroreparative therapeutics, focusing primarily on spinal cord injuries and other neurologic conditions. With its lead product, NVG-291, showing potential as a groundbreaking treatment for chronic tetraplegia, the upcoming events that NervGen will participate in, including the H.C. Wainwright "HCW@Home" series and the 2026 Bloom Burton & Co. Healthcare Investor Conference, present significant opportunities for the company and its investors.
Investor participation in these conferences can yield valuable insights into the company's strategy and future prospects. NervGen's engagement in these events, particularly with a key presentation at the Bloom Burton Conference on April 22, 2026, highlights its commitment to transparency and investor relations while potentially enhancing investor interest in its innovative solutions for conditions with high unmet medical needs.
NervGen’s recent FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for NVG-291 signal a favorable regulatory outlook, which could expedite its commercialization process. Investors should closely watch the data emerging from ongoing clinical trials, particularly the anticipated results from the Phase 1b/2a CONNECT SCI study, which could establish NVG-291 as a pioneering treatment in its category.
However, potential investors should approach with caution, as the biopharmaceutical sector is inherently volatile, with the company's future heavily dependent on successful trial outcomes, regulatory approvals, and ongoing funding. According to the management's discussion in their latest reports, apprehensions surrounding financial projections, competition, and clinical development hurdles merit careful consideration.
In summary, NervGen Pharma holds strong potential as an investment opportunity, but prospective investors should weigh the risks against the possible high rewards stemming from its promising therapeutic candidates. Engage with the company’s presentations for real-time updates and insights into their strategic direction.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate in the H.C. Wainwright “HCW@Home” series and the 2026 Bloom Burton & Co. Healthcare Investor Conference.
H.C. Wainwright “HCW@Home” Series, April 15, 2026
| Format: | Fireside Chat |
| Date: | Wednesday, April 15th |
| Time: | 1:00 – 2:00 pm ET |
| Location: | Virtual |
| Webcast: | Register Here |
2026 Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026
| Format: | Corporate Presentation and 1x1 Investor Meetings |
| Presentation Date: | Wednesday, April 22nd |
| Time: | 11:00 – 11:30 am ET |
| Location: | Toronto, Ontario |
| Webcast: | Register Here |
A live webcast and archived replay of the presentations will be available on the investors section of www.nervgen.com.
About NervGen Pharma
NervGen Pharma Corp. (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTP? pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Contacts
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
Cautionary Note Regarding Forward Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company's potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; NVG-291 as potentially the first approved pharmacologic treatment for chronic tetraplegia; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's most recently filed Annual Information Form, which is available under the Company’s profile on SEDAR+ at www.sedarplus.ca (which are also incorporated in the recently filed form 40-F available on the website of the U.S. Securities and Exchange Commission (the “SEC") at www.sec.gov), including the management’s discussion & analysis for the year-ended December 31, 2025. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
FAQ**
How does NervGen Pharma Corp. NGEN plan to leverage its Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency to expedite the development of NVG-291 for spinal cord injury treatment?
What insights can we expect from the upcoming H.C. Wainwright “HCW@Home” series regarding NervGen Pharma Corp. NGEN's strategic direction and future clinical trial outcomes, especially for NVG-291?
In what ways does NervGen Pharma Corp. NGEN intend to address potential funding challenges for further development of NVG-291 and upcoming therapeutics like NVG-300 during the 2026 Bloom Burton & Co. Healthcare Investor Conference?
Can NervGen Pharma Corp. NGEN provide updates on its clinical trial progress and expected timelines for NVG-291's commercialization during the upcoming investor conferences?
**MWN-AI FAQ is based on asking OpenAI questions about NervGen Pharma Corp. (NASDAQ: NGEN).
NASDAQ: NGEN
NGEN Trading
-0.45% G/L:
$3.7332 Last:
111,347 Volume:
$3.75 Open:
